|1.||Hayakawa, Masahiro: 2 articles (12/2009 - 12/2006)|
|2.||Kajikuri, J: 2 articles (09/2000 - 08/2000)|
|3.||Itoh, T: 2 articles (09/2000 - 08/2000)|
|4.||Suzuki, Y: 2 articles (09/2000 - 08/2000)|
|5.||Suzumori, K: 2 articles (09/2000 - 08/2000)|
|6.||Shimizu, Takahiro: 1 article (03/2014)|
|7.||Suzuki, Tomoyuki: 1 article (03/2014)|
|8.||Takahashi, Yuta: 1 article (03/2014)|
|9.||Tsukada, Kazuhiro: 1 article (03/2014)|
|10.||Fujii, Takuto: 1 article (03/2014)|
|1.||Nephrotic Syndrome (Syndrome, Nephrotic)
08/01/1996 - "For the purpose of clarifying the changes occurring in thromboxane (TX)A2 metabolism in the platelet of nephrosis patients, we investigated the changes in platelet sensitivity to TXA2 and the changes in TXA2 production in pediatric patients with nephrotic syndrome (N.S.) using STA2 which is an analogue of TXA2 and ONO 3708 which is a TXA2 receptor antagonist. "
01/01/1997 - "In order to examine the intracellular thromboxane A2 (TXA2) signal transduction system in platelets of patients with nephrotic syndrome, we measured the levels of TXA2 metabolites in urine and blood and platelet calcium ion level as a result of STA2, an analog of STA2 (9,11-dimethylmethano-11,12-methano-TXA2) stimulation, and obtained the following results: (1) In pediatric patients with nephrotic syndrome, urinary thromboxane B2 (TXB2) and 11-dehydro-TXB2 excretion were signficantly higher in the onset and relapse groups compared to the remission and control groups. "
|2.||Pulmonary Hypertension (Ayerza Syndrome)
|3.||Fetal Growth Retardation (Intrauterine Growth Retardation)
12/01/2006 - "We developed an animal model of IUGR in which fetal growth restriction was induced by administering a synthetic thromboxane A(2) analogue (STA(2)) to the mother. "
05/01/2000 - "We have developed a new rat model of IUGR using maternal administration of synthetic thromboxane A(2) (STA(2)). "
12/01/2009 - "Maternal rats were divided randomly into three groups, STA2-/Soy (Sham), STA2+/Soy (IUGR), and STA2+/DHA (DHA) groups. "
12/01/2009 - "To determine whether the intrauterine environment affects lipid metabolism, we measured the fatty acid composition of the brain in rats with intrauterine growth retardation (IUGR) induced by synthetic thromboxane A2 (STA2). "
06/01/1999 - "IUGR was induced by maternal administration of synthetic thromboxane A2 (STA2) from the 13th day of gestation. "
|4.||Astrocytoma (Pilocytic Astrocytoma)
01/01/1992 - "On the other hand, STA2, a TXA2 receptor analogue, also accumulated IP3 in human astrocytoma cells. "
05/01/1992 - "[3H]ONO NT-126 binding was displaced by ONO NT-126, S-145, SQ29548, STA2 and U46619 with Ki values (nM) of 0.21, 1.14, 7.05, 23.5 and 235 in astrocytoma cell membranes and 0.23, 5.55, 259, 9.25 and 43.7 in platelet membranes, respectively. "
01/01/1992 - "TXA2-receptor antagonists (ONO NT-126, S-145, SQ29548 and ONO3708) concentration-dependently inhibited PIP2-specific PLase C activation by STA2, and they also inhibited [3H]SQ 29548 binding in human astrocytoma cells. "
03/01/1995 - "9,11-Epithio-11,12-methanothromboxane A2 (STA2), a stable analogue of thromboxane A2 (TXA2), activated GTPase in membranes derived from human astrocytoma cells, rabbit astrocytes and human platelets with different potencies. "
|5.||Weight Loss (Weight Reduction)
12/01/2006 - "Fetuses and neonates from the STA(2) group showed a highly significant weight reduction throughout the observation period from day 19 of gestation to postnatal day 7. Weight reduction near and at term exceeded 10% and became more pronounced during the first week after birth. "
12/01/1996 - "STA2 transiently increased liver weight loss (-3.6 g/100 g liver weight), followed by a gradual weight gain (9.0 g/100 g). "
|1.||Thromboxane A2 (A2, Thromboxane)
|7.||tranilast (N 5')
|8.||GTP Phosphohydrolases (GTPases)
|9.||15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
|10.||Nitroarginine (NG Nitro L Arginine)
|1.||Indwelling Catheters (Arterial Line)